Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

HIV Infection

Free Subscription 07.09.2026 5 AIDS 1 Antimicrob Agents Chemother 1 Br J Haematol 4 Clin Infect Dis 11 J Acquir Immune Defic Syndr 4 J Infect Dis 2 J Med Virol 1 Lancet Infect Dis 1 PLoS Comput Biol 1 PLoS Med 4 PLoS One 1 Proc Natl Acad Sci U S A 2 Vaccine 1 Virology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AIDS

1. RIEMANN L, Boger L, Dahl C, Gemoll T, et al
   Circulating markers of organ damage associate with COPD in people with HIV: an exploratory proteomic analysis.
   AIDS. 2026 Sep 3. doi: 10.1097/QAD.0000000000004618.
   PubMed         Abstract available
   
   
2. PARCZEWSKI M, Zazzi M, Mielczak K, Bohm M, et al
   Efficacy of dolutegravir or bictegravir-containing therapy in a real-life cohort of people with HIV-1 sub-subtype A6.
   AIDS. 2026 Sep 2. doi: 10.1097/QAD.0000000000004610.
   PubMed         Abstract available
   
   
3. CABELLO-UBEDA A, Riggs PK, Honerkamp-Smith G, Wells A, et al
   Sex-modulated associations between cytomegalovirus cell-associated DNA and cognition in people with HIV on ART.
   AIDS. 2026 Sep 2. doi: 10.1097/QAD.0000000000004617.
   PubMed         Abstract available
   
   
4. BERENGUER J, Ryan P, Ramos-Ruperto L, Martin-Carbonero L, et al
   Clinical phenotypes and incidence of acute or recent hepatitis C virus infection and bacterial sexually transmitted infections among MSM with HIV.
   AIDS. 2026 Sep 2. doi: 10.1097/QAD.0000000000004614.
   PubMed         Abstract available
   
   
5. FILIP I
   Cardiovascular risk prediction in people with HIV: looking beyond low-density lipoprotein cholesterol.
   AIDS. 2026 Aug 31. doi: 10.1097/QAD.0000000000004612.
   PubMed        
   
   

   
   Antimicrob Agents Chemother

6. GUO Y, Li Y, Zhao P, Bi J, et al
   Safety and pharmacokinetics of CL-197, a potent compound with low cytotoxicity against HIV-1: a randomized, double-blind, placebo-controlled, first-in-human phase 1 clinical trial.
   Antimicrob Agents Chemother. 2026 Sep 4:e0098426. doi: 10.1128/aac.00984.
   PubMed         Abstract available
   
   

   
   Br J Haematol

7. MERLI M, Bianchi B, Bibas M, Dalu D, et al
   Role of direct-acting antivirals in people with HIV-associated non-Hodgkin lymphoma and concomitant HCV infection: A study on behalf of the Fondazione Italiana Linfomi.
   Br J Haematol. 2026 Sep 4. doi: 10.1111/bjh.70793.
   PubMed         Abstract available
   
   

   
   Clin Infect Dis

8. CHIOSI JJ, Freedberg KA
   Long-acting injectable antiretroviral therapy for people with HIV and adherence challenges to oral medications: From trials to implementation.
   Clin Infect Dis. 2026 Sep 1:ciag506. doi: 10.1093.
   PubMed        
   
   
9. CHEN NY, Chen CP, Lin YC, Cheng SH, et al
   Direct Initiation of Long-Acting Cabotegravir Plus Rilpivirine in People with HIV and Suboptimal Virologic Suppression: A Randomized Trial.
   Clin Infect Dis. 2026 Sep 1:ciag504. doi: 10.1093.
   PubMed         Abstract available
   
   
10. HAVENS JP, O'Neill J, Kubat M, Davis JM, et al
    Financial Impact of a Long-Acting Injectable Cabotegravir/Rilpivirine Program: A Real-World Experience.
    Clin Infect Dis. 2026 Sep 1:ciag537. doi: 10.1093.
    PubMed         Abstract available
    
    
11. MCKENNA L, Frick M, Alarcon-Guizado VA, Davies GR, et al
    When are Uncontrolled Trials in TB Scientifically and Ethically Justified: Borrowing Wisdom From Early AIDS Clinical Trials.
    Clin Infect Dis. 2026;83:e399-e403.
    PubMed         Abstract available
    
    

    
    J Acquir Immune Defic Syndr

12. LUJINTANON S, Lesko CR, Haw NJL, Hickey MD, et al
    Impact of implementation process on long-acting cabotegravir/rilpivirine prescription at 9 HIV clinics, 2021-2024.
    J Acquir Immune Defic Syndr. 2026 Aug 31:10.1097/QAI.0000000000003970.
    PubMed         Abstract available
    
    
13. BAUERMEISTER JA, Choi SK, Lin W, Cheshure A, et al
    A Prospective, Youth-Led Mystery Shopper Assessment of Six Ending the HIV Epidemic Jurisdictions in Florida.
    J Acquir Immune Defic Syndr. 2026 Aug 31. doi: 10.1097/QAI.0000000000003969.
    PubMed         Abstract available
    
    
14. LOGIE CH, Admassu Z, Okumu M, MacKenzie F, et al
    Longitudinal associations between condom use self-efficacy trajectories, HIV-related stigma, and HIV prevention engagement among refugee youth in Kampala, Uganda.
    J Acquir Immune Defic Syndr. 2026 Sep 2. doi: 10.1097/QAI.0000000000003933.
    PubMed         Abstract available
    
    
15. SPRINGER SA, Di Paola A, Kuo I, Knight K, et al
    Long-acting Injectable Pre-Exposure Prophylaxis Preference for Persons Who Use Drugs and are Involved with the Criminal Legal System.
    J Acquir Immune Defic Syndr. 2026 Sep 2. doi: 10.1097/QAI.0000000000003931.
    PubMed         Abstract available
    
    
16. MOYLE G, Radtchenko J, Gruber J, Dunbar M, et al
    Weight trajectories in virally suppressed people with HIV compared to matched people without HIV, and predictors of weight gain: a 3-year cohort study from the US TRIO Healthcare Network.
    J Acquir Immune Defic Syndr. 2026 Sep 2. doi: 10.1097/QAI.0000000000003932.
    PubMed         Abstract available
    
    
17. WANG Y, Logie CH, Hasham A, Mackay KI, et al
    Trends in HIV prevention outcomes among Northern and Indigenous adolescents: A repeated cross-sectional study of arts-based sexual health workshops in the Northwest Territories, Canada.
    J Acquir Immune Defic Syndr. 2026 Sep 4. doi: 10.1097/QAI.0000000000003965.
    PubMed         Abstract available
    
    
18. VELLOZA J, Adler A, Chakravarty D, Glidden DV, et al
    Associations between self-reported PrEP use and short and long-term pharmacologic metrics of PrEP adherence among Kenyan women.
    J Acquir Immune Defic Syndr. 2026 Sep 4. doi: 10.1097/QAI.0000000000003967.
    PubMed         Abstract available
    
    
19. BEER L, Crim SM, Tie Y, O'Shea J, et al
    Prescription of Long-Acting Antiretroviral Therapy Among U.S. Adults with HIV.
    J Acquir Immune Defic Syndr. 2026 Sep 4. doi: 10.1097/QAI.0000000000003963.
    PubMed         Abstract available
    
    
20. JAYADEVAPPA R, Morales K, Hanumali R, Metzger D, et al
    Association between retention in HIV care, psychiatric comorbidities, and outcomes in veterans with HIV.
    J Acquir Immune Defic Syndr. 2026 Sep 4. doi: 10.1097/QAI.0000000000003966.
    PubMed         Abstract available
    
    
21. DUARTE MJ, Tien PC, Kuniholm MH, Ma Y, et al
    PREVALENCE AND SEVERITY OF STEATOTIC LIVER DISEASE IN WOMEN WITH AND WITHOUT HIV.
    J Acquir Immune Defic Syndr. 2026 Sep 4. doi: 10.1097/QAI.0000000000003964.
    PubMed         Abstract available
    
    
22. ADEOJO LW, Pauls C, Swaim D, Kumar P, et al
    Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Rivaroxaban with Cobicistat or Darunavir/Cobicistat in Healthy Participants.
    J Acquir Immune Defic Syndr. 2026 Sep 4. doi: 10.1097/QAI.0000000000003971.
    PubMed         Abstract available
    
    

    
    J Infect Dis

23. KJAERGAARD VS, Ledergerber B, Bannister W, Cortez Cardoso Penha R, et al
    Factors Associated with Persistently Increased IL-6 Levels in People with HIV.
    J Infect Dis. 2026 Sep 3:jiag451. doi: 10.1093.
    PubMed         Abstract available
    
    
24. CRAIN CR, Gaiha GD, Gandhi RT
    Buying Time: T cells and Delayed HIV Rebound After Treatment Interruption.
    J Infect Dis. 2026 Sep 3:jiag449. doi: 10.1093.
    PubMed        
    
    
25. ANDERSEN AB, Juhl AK, Gunst JD, Rasmussen TA, et al
    Functional T Cell Responses Are Associated With Prolonged HIV Control After Treatment Interruption.
    J Infect Dis. 2026 Sep 2:jiag448. doi: 10.1093.
    PubMed         Abstract available
    
    
26. EDGAR JE, Parker HR, Thobakgale C, Adland E, et al
    Immune control of HIV viraemia in early paediatric infection is associated with induction of HIV-specific CD8+ T-cell activity following multiple treatment interruptions.
    J Infect Dis. 2026 Aug 29:jiag440. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Med Virol

27. HARA Y, Kitamura H, Matsuda K, Fujisaki C, et al
    Identification of a Novel Small Molecule Facilitating HIV Elimination by the "Shock-And-Kill" Approach.
    J Med Virol. 2026;98:e71131.
    PubMed         Abstract available
    
    
28. GAO J, Ma M, Zhang Y, Wang X, et al
    Comparative Analysis of NAT, TRFIA, and ELISA for Screening Blood-Borne Pathogens in Preoperative and Pre-Transfusion Patients.
    J Med Virol. 2026;98:e71125.
    PubMed         Abstract available
    
    

    
    Lancet Infect Dis

29. BADEN LR, Shah NS, Liu STH, Cohen J, et al
    Nirmatrelvir-ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet Infect Dis. 2026 Aug 31:S1473-3099(26)00406.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

30. ROBERTS JA, Teslya A, Kretzschmar ME, van de Wijgert JHHM, et al
    Prospects of HIV elimination among men who have sex with men: A systematic review of modeling studies.
    PLoS Comput Biol. 2026;22:e1014596.
    PubMed         Abstract available
    
    

    
    PLoS Med

31. MODY A, Sikombe K, Simbeza S, Mukamba N, et al
    Effect of a person-centered care intervention on return and sustained reengagement after treatment interruptions from HIV care in Zambia: A post-hoc analysis of a stepped-wedged cluster randomized trial.
    PLoS Med. 2026;23:e1005052.
    PubMed         Abstract available
    
    

    
    PLoS One

32. JOHNSON-PERETZ J, Ayieko J, Owino L, Akatukwasa C, et al
    Participant perspectives on a person-centred care model for mobile individuals in HIV care from the SEARCH Dynamic Choice Treatment trial in rural Kenya and Uganda.
    PLoS One. 2026;21:e0356605.
    PubMed         Abstract available
    
    
33. MATOLA BW, Nyasulu JCY, Nicol E
    Investigating strategies to enhance access to HIV services among children in Malawi: A multifaceted research approach, study protocol.
    PLoS One. 2026;21:e0357408.
    PubMed         Abstract available
    
    
34. ZEWUDE BM, Mekonnin WT, Tola DA, Rufe NB, et al
    Prevalence of intestinal parasites and associated factors among HIV patients receiving antiretroviral therapy at public hospitals in North Shoa Zone, Oromia, Ethiopia: Cross-sectional study.
    PLoS One. 2026;21:e0357660.
    PubMed         Abstract available
    
    
35. MALANDE OO, Deogratias M, Songok JJ, Hassan S, et al
    Strengthened HPV vaccination among adolescents living with HIV, - Findings of a Pilot QI project in Kampala Metropolitan, Uganda.
    PLoS One. 2026;21:e0356686.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

36. AMESIMEKU WAO, Nakata Y, Monde N, Terasawa H, et al
    Lenacapavir binding to immature Gag induces giant virions and causes protease-dependent inhibition of viral release.
    Proc Natl Acad Sci U S A. 2026;123:e2609634123.
    PubMed         Abstract available
    
    

    
    Vaccine

37. ARROYO L, Raeman R, Iyer SS
    Acute immunometabolic reprogramming following clade C HIV immunization in rhesus macaques.
    Vaccine. 2026;92:129115.
    PubMed         Abstract available
    
    
38. ZHANG J, Askenase P, Crumpacker C
    A leap forward in vaccination - a molecular process of epigenetic silencing to the virus.
    Vaccine. 2026;91:129119.
    PubMed         Abstract available
    
    

    
    Virology

39. KUMAR M, Bhowmik R, Kumar S, Topno RK, et al
    Immunopathogenesis of TB-HIV Co-Infection: Mechanisms of Dual Immune Suppression and Viral-Bacterial Synergy.
    Virology. 2026;624:111054.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO HIV Infection is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum